(Source: Enanta Pharmaceuticals Inc) New data to be presented on EDP-494, Enanta's pan-genotypic cyclophilin inhibitor for Hepatitis C virus New data to be presented on AbbVie's investigational, pan-genotypic regimen consisting of ABT-493, Enanta's second protease inhibitor, in combination with ABT-530, AbbVie's NS5A inhibitor WATERTOWN, Mass.--(BUSINESS WIRE)--Mar. 30, 2016-- Enanta Pharmaceuticals, Inc., (NASDAQ: ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today announced that several abstracts regarding regimens containing either ABT-493 or paritaprevir, Enanta's protease inhibitors...
↧